Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (9637)	4/15/1999 11:03:00 AM
From: opalapril	Read Replies (2) \| Respond to of 17367

I am never angry, dammit all. Often disgusted, frequently bemused. The phone number was in an email/fax message sent by a cyberspace correspondent of mine who apparently subscribes to some kind of news service.

To: aknahow who wrote (9637)	4/15/1999 8:48:00 PM
From: Cacaito	Read Replies (2) \| Respond to of 17367

george w., I agree with you, 25% is very fair, indeed very good. They are going to share the profits AND the costs of development in a Xoma 25%/GNE 75% basis. They are also going to provide Xoma's 25% share of the costs as a long term long, good, this is almost free. The Floorless nature is not so bad coming from GNE vs the "private placements". It is more difficult for a company like GNE to short without proving intention to influence the price vs the "privy place" ones. The worse is to be acquire. And Xoma gets royalties from sales abroad, even 5% is good. Xoma's leverage to deal with Big Pharma the Bpi issue is improved a lot. And GNE is second to none in prestige, probably the most prestigious one.